Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.

April 30, 2008 09:00 ET

Ambrilia to Present at BioFinance 2008

MONTREAL, QUEBEC--(Marketwire - April 30, 2008) - Ambrilia Biopharma Inc. (TSX:AMB) today announced that Dr. Philippe Calais, President and Chief Executive Officer, will present the Company and its projects at BioFinance 2008 to be held in Toronto, May 6-8. This presentation will take place on Wednesday, May 7, at 3:00 pm local time, in the Trinity I room.


Ambrilia Biopharma Inc. (TSX:AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. In the latter part of 2007, Ambrilia adopted a new strategic plan, the primary objective of which is to progressively refocus R&D activities solely on antivirals. The strategy aims to capitalize on the Company's broad portfolio and original expertise in virology. Today, Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery platform for cancer, a HIV protease inhibitor program (exclusive worldwide rights granted to Merck & Co., Inc.), HIV integrase inhibitor and entry inhibitor programs, and a HCV polymerase inhibitor program. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company's web site:

Contact Information